Protara Therapeutics reports Q2 EPS ($1.00), consensus (80c)

“Following the positive preliminary data from the dose escalation portion of the ADVANCED-1 trial of TARA-002 in patients with high-grade non-muscle invasive bladder cancer, we have seen rapid enrollment in the expansion portion of the trial and anticipate sharing preliminary results in the first half of 2024,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We are building on this momentum, and plan to initiate two additional trials for TARA-002 later this year while continuing to maintain a disciplined approach to investments. We are in a solid financial position with cash runway into 2025.”